BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30

뉴스 본문을 불러오고 있어요.

BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30 | 웨이프 WAPE

BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30

기사 요약

관련 종목

댓글 —